Literature DB >> 8943663

Bioreductive agents, hypoxic cells and therapy.

T A Connors.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8943663     DOI： 10.1016/0959-8049(96)00305-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  Remembering the Host in Tuberculosis Drug Development.

Authors:  Daniel J Frank; David J Horne; Noton K Dutta; Moagi Tube Shaku; Rajhmun Madensein; Thomas R Hawn; Adrie J C Steyn; Petros C Karakousis; Bavesh Davandra Kana; Graeme Meintjes; Barbara Laughon; Zaid Tanvir
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

Review 2.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

Review 4.  Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.

Authors:  Roger M Phillips
Journal:  Cancer Chemother Pharmacol       Date:  2016-01-25       Impact factor: 3.333
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.